{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:21:16Z","timestamp":1761657676364,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"vor","delay-in-days":1673,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jmii.2010.08.003","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T01:46:47Z","timestamp":1295833607000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia"],"prefix":"10.1016","volume":"44","author":[{"given":"Ching-Lan","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing-Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2010.08.003_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1086\/317491","article-title":"Disorders of glucose metabolism in patients infected with human immunodeficiency virus","volume":"31","author":"Dube","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib4","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/317477","article-title":"Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d\u2019Epidemiologie Clinique du Syndrome d\u2019Immunodeficience Acquise en Aquitaine","volume":"31","author":"Thi\u00e9baut","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2010.08.003_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1468-1293.2008.00687.x","article-title":"Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study","volume":"10","author":"Lo","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-M\u00f8ller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00126334-200003010-00009","article-title":"Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d\u2019Epidemiologie Clinique du Sida en Aquitaine (GECSA)","volume":"23","author":"Thiebaut","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2010.08.003_bib9","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2010.08.003_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0924-8579(03)00100-6","article-title":"Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy","volume":"22","author":"Calza","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2010.08.003_bib11","first-page":"10","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"3","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2010.08.003_bib12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Sav\u00e8s","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2010.08.003_bib14","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2010.08.003_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1469-0691.2000.00163.x","article-title":"Management of dyslipidemia in patients with HIV disease","volume":"6","author":"Manfredi","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2010.08.003_bib16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.ATV.20.12.2625","article-title":"HIV protease inhibitors stimulate hepatic triglyceride synthesis","volume":"20","author":"Lenhard","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jmii.2010.08.003_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0166-3542(00)00102-9","article-title":"HIV protease inhibitors block adipogenesis and increase lipolysis in vitro","volume":"47","author":"Lenhard","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jmii.2010.08.003_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200411050-00005","article-title":"The effects of HIV protease inhibitors atazanavir and lopinavir\/ritonavir on insulin sensitivity in HIV-seronegative healthy adults","volume":"18","author":"Noor","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2010.08.003_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2010.08.003_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14787210.1.3.403","article-title":"Atazanavir: improving the HIV protease inhibitor class","volume":"1","author":"Becker","year":"2003","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jmii.2010.08.003_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2010.08.003_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/154510970400300304","article-title":"Atazanavir\u2014a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials","volume":"3","author":"Cahn","year":"2004","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"10.1016\/j.jmii.2010.08.003_bib25","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/00002030-200306130-00008","article-title":"Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial","volume":"17","author":"Haas","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2010.08.003_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkm413","article-title":"Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial","volume":"61","author":"Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2010.08.003_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2310\/JIM.0b013e3181641b26","article-title":"Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir\/ritonavir","volume":"56","author":"Busti","year":"2008","journal-title":"J Investig Med"},{"key":"10.1016\/j.jmii.2010.08.003_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1592\/phco.28.3.323","article-title":"Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus","volume":"28","author":"Nguyen","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jmii.2010.08.003_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-06-0648","article-title":"Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects","volume":"156","author":"Guffanti","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jmii.2010.08.003_bib31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.jmii.2010.08.003_bib32","first-page":"67","article-title":"Differentiation of HIV protease inhibitors in models of lipid and glucose metabolism and gene expression in adipocytes [abstract 100]","volume":"6","author":"Parker","year":"2001","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jmii.2010.08.003_bib33","first-page":"L6","article-title":"Differentiation of atazanavir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis, and proteasome function [abstract 10]","volume":"7","author":"Wang","year":"2002","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jmii.2010.08.003_bib34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00126334-200406010-00005","article-title":"Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir","volume":"36","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2010.08.003_bib35","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/11.24.3039","article-title":"Relative contribution of variation within the APOC3\/A4\/A5 gene cluster in determining plasma triglycerides","volume":"11","author":"Talmud","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jmii.2010.08.003_bib36","doi-asserted-by":"crossref","first-page":"21553","DOI":"10.1074\/jbc.M411412200","article-title":"Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase","volume":"280","author":"Merkel","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jmii.2010.08.003_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1086\/597099","article-title":"Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan","volume":"48","author":"Chang","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib38","first-page":"174","article-title":"Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia","volume":"39","author":"M\u00f6bius","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2010.08.003_bib39","series-title":"Abstract book of the 40th interscience conference on antimicrobial agents and chemotherapy","article-title":"Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinivir [abstract 1645]","author":"O\u2019Mara","year":"2000"},{"issue":"Suppl 2","key":"10.1016\/j.jmii.2010.08.003_bib40","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2010.08.003_bib41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jac\/dkl074","article-title":"Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir","volume":"57","author":"Pineda","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2010.08.003_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/hct1004-269","article-title":"Short-term effect of ritonavir-boosted atazanavir in hepatitis B and\/or C co-infected, treatment-experienced HIV patients","volume":"10","author":"P\u00e9rez-El\u00edas","year":"2009","journal-title":"HIV Clin Trials"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118211000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118211000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:16:21Z","timestamp":1761657381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118211000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1684118211000508"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2010.08.003","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2010.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}